Groundbreaking Sound Based Technology to Ablate Renal Cancer
Dr. David Schulsinger spearheads pilot study for ablation of renal cell carcinoma with SonaCare Medical’s Sonatherm® Laparoscopic Soft Tissue HIFU Surgical Ablation Device.10/29/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 29, 2014 Category: Cancer & Oncology Source Type: news

Kidney cancer in Central Europe
(European Molecular Biology Laboratory) Large-scale DNA and RNA sequencing of renal cell carcinoma patients in Europe reveals primary causes of kidney cancer vary between populations. Findings provide insights into the genetic architecture of clear-cell renal-cell carcinoma. Association between cancer incidence and exposure to aristolochic acid -- an ingredient in some herbal remedies -- has implications for public health, particularly in Romania. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 29, 2014 Category: Cancer & Oncology Source Type: news

Correlation of radiographic renal cell carcinoma tumor volume utilizing computed tomography
and magnetic... http://t.co/gDZZ5poX7s — UroToday.com (@urotoday) September 10, 2014 09/11/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 11, 2014 Category: Cancer & Oncology Source Type: news

Correlation of radiographic renal cell carcinoma tumor volume utilizing computed tomography
and magnetic... http://t.co/gDZZ5poX7s — UroToday.com (@urotoday) September 10, 2014 09/11/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 11, 2014 Category: Urology & Nephrology Source Type: news

Correlation of radiographic renal cell carcinoma tumor volume utilizing computed tomography
and magnetic...http://t.co/gDZZ5poX7s— UroToday.com (@urotoday)September 10, 201409/11/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 11, 2014 Category: Urology & Nephrology Source Type: news

Treatment of kidney cancer with a novel nanoparticle
Certain nanoparticles (NP) emit heat energy when excited by near-infrared (NIR) laser energy. We determined efficacy of a novel nanoparticle to induce hyperthermic cellular death of renal cell carcinoma in vitro.09/09/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 9, 2014 Category: Cancer & Oncology Source Type: news

Adjuvant Therapy for RCC
At the present time, the standard of care for patients who have received nephrectomy for localized renal cell carcinoma (RCC) is radiographic surveillance.09/05/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 5, 2014 Category: Cancer & Oncology Source Type: news

Targeted Therapies in Advanced Renal Cell CarcinomaTargeted Therapies in Advanced Renal Cell Carcinoma
Are metastatic sites associated with survival in patients with renal cell carcinoma treated with targeted therapies? Future Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 5, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line RCC Treatment
The combination of gemcitabine plus capecitabine and sunitinib (GCS) shows activity in metastatic renal cell carcinoma (mRCC).09/04/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 4, 2014 Category: Cancer & Oncology Source Type: news

Anti-tumor effect of ribavirin in combination with interferon-alpha on renal cell carcinoma cell lines in vitro
Ribavirin is an anti-viral drug; however, recent data suggest that it may also be effective in cancer therapy.09/03/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 3, 2014 Category: Cancer & Oncology Source Type: news

mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma
Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors.09/03/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 3, 2014 Category: Cancer & Oncology Source Type: news

Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to...
MarketOptimizer.org adds “EpiCast Report Renal Cell Carcinoma - Epidemiology Forecast to 2023” to its store. This forecast is supported by age- and sex-specific data for the incidence.(PRWeb September 01, 2014)Read the full story at http://www.prweb.com/releases/2023-renal-cell-carcinoma/market-epidemiology/prweb12135554.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 2, 2014 Category: Pharmaceuticals Source Type: news

New agents and new targets for renal cell carcinoma
The vascular endothelial growth factor (VEGF) pathway blockers and mammalian target of rapamycin (mTOR) inhibitors have dramatically improved the treatment options and outcome for patients with advanced renal cell carcinoma (RCC).08/29/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2014 Category: Cancer & Oncology Source Type: news

Diabetes mellitus is independently associated with an increased risk of mortality among clear cell renal cell carcinoma patients
Conflicting data exist regarding the interaction of diabetes mellitus (DM) with outcomes for patients with renal cell carcinoma (RCC).08/23/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 23, 2014 Category: Cancer & Oncology Source Type: news

The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
Comprehensive molecular analysis is performed on 66 kidney chromophobe cases08/22/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 22, 2014 Category: Cancer & Oncology Source Type: news

MEDIA AVAILABILITY: Rare kidney tumor provides insights on role of metabolic changes in cancer
Researchers in The Cancer Genome Atlas (TCGA) Network have made a number of new findings about the biology and development of a rare form of kidney cancer. They found that the disease - chromophobe renal cell carcinoma (ChRCC) - stems in part from alterations in genes in the mitochondria, the cell's energy supplier. (Source: NHGRI Press Releases)
Source: NHGRI Press Releases - August 21, 2014 Category: Genetics & Stem Cells Source Type: news

Practice Update: Renal Cell Carcinoma
Improve patient care by participating in The West Cancer Center Tumor Boards or start your own case discussions.08/21/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 21, 2014 Category: Cancer & Oncology Source Type: news

Phase 1 Clinical Trial of Antibody-Drug Conjugate SGN-CD70A for Non-Hodgkin Lymphoma and Renal Cell Carcinoma
"CD70 is a very promising ADC antigen, which is highly expressed in both NHL and RCC, and has minimal expression in healthy tissues," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development, at Seattle Genetics.08/21/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 21, 2014 Category: Cancer & Oncology Source Type: news

Extremely delayed brain metastasis from renal cell carcinoma
Brain metastasis occurs in 3.9-24% of patients with renal cell carcinoma (RCC), with an average interval from nephrectomy to brain metastasis of 1 to 3 years.08/15/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 15, 2014 Category: Cancer & Oncology Source Type: news

Seattle Genetics begins Phase I trial of lymphoma and carcinoma drug SGN-CD70A
Seattle Genetics has initiated a Phase I clinical trial assessing SGN-CD70A for CD70-positive relapsed or refractory non-Hodgkin lymphoma (NHL) and metastatic renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 13, 2014 Category: Pharmaceuticals Source Type: news

Renal Cell Cancer
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 28, 2014 Category: Journals (General) Source Type: news

OncoBriefs: Local Tx for mRCC, Cervical Ca Prevention (CME/CE)
(MedPage Today) -- More than 80% of patients with metastatic renal cell carcinoma remained alive without disease progression 3 years after image-guided local ablation of tumors, a retrospective study showed. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - July 27, 2014 Category: Endocrinology Source Type: news

A New Target for Fighting Clear Cell RCC?
Scientists have discovered a new molecular target for therapy to fight clear cell renal cell carcinoma (RCC)...07/26/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 26, 2014 Category: Cancer & Oncology Source Type: news

Partial nephrectomy retains edge over radical nephrectomy in larger renal tumors
Patients with renal cell carcinoma tumours larger than 4 cm benefit from undergoing elective partial nephrectomy (PN) rather than radical nephrectomy (RN) surgery, a study has found.07/24/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 24, 2014 Category: Cancer & Oncology Source Type: news

Cytoreductive nephrectomy can benefit patients with mRCC
Patients treated with targeted therapy for metastatic renal cell carcinoma (mRCC) may derive significant survival benefit from cytoreductive nephrectomy (CN), particularly if their initial prognosis is good, study findings indicate.07/24/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 24, 2014 Category: Cancer & Oncology Source Type: news

Functional Genomics in Clear Cell Renal Cell CarcinomaFunctional Genomics in Clear Cell Renal Cell Carcinoma
Functional genomics has identified 31 potential therapeutic targets that contribute to clear cell renal cell carcinoma (ccRCC) proliferation, researchers report. Reuters Health Information (Source: Medscape Nephrology Headlines)
Source: Medscape Nephrology Headlines - July 21, 2014 Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news

Immunotherapy for Kidney Cancer
Joseph I. Clark, MD Immunotherapy, a type of treatment designed to enhance or restore the body’s ability to fight cancerous cells by activating the immune system, has long been a mainstay of treatment for kidney cancer, and continues to attract considerable attention from oncologists and patients alike. The attention is not only due to the clinical benefits that patients continue to experience with immunotherapy, but also to the apparent promise of newer immunotherapeutic agents that are currently being investigated in clinical trials. Although surgical resection (removal) of the kidney is often used in patient...
Source: Kidney Cancer Association - July 19, 2014 Category: Cancer & Oncology Source Type: news

Immunotherapy for Kidney Cancer
Joseph I. Clark, MD Immunotherapy, a type of treatment designed to enhance or restore the body’s ability to fight cancerous cells by activating the immune system, has long been a mainstay of treatment for kidney cancer, and continues to attract considerable attention from oncologists and patients alike. The attention is not only due to the clinical benefits that patients continue to experience with immunotherapy, but also to the apparent promise of newer immunotherapeutic agents that are currently being investigated in clinical trials. Although surgical resection (removal) of the kidney is often used in patients wi...
Source: Kidney Cancer Association - July 19, 2014 Category: Urology & Nephrology Source Type: news

Immunotherapy for Kidney Cancer
Joseph I. Clark, MDImmunotherapy, a type of treatment designed to enhance or restore the body’s ability to fight cancerous cells by activating the immune system, has long been a mainstay of treatment for kidney cancer, and continues to attract considerable attention from oncologists and patients alike. The attention is not only due to the clinical benefits that patients continue to experience with immunotherapy, but also to the apparent promise of newer immunotherapeutic agents that are currently being investigated in clinical trials.Although surgical resection (removal) of the kidney is often used in patients with l...
Source: Kidney Cancer Association - July 19, 2014 Category: Urology & Nephrology Source Type: news

Mayo Clinic researchers reveal treasure trove of genes key to kidney cancer
(Mayo Clinic) A genomic analysis of clear cell renal cell carcinoma, the most common form of kidney cancer, from 72 patients has uncovered 31 genes that are key to development, growth and spread of the cancer, say researchers from Mayo Clinic in Florida. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 1, 2014 Category: Global & Universal Source Type: news

Mayo Clinic Researchers Reveal Treasure Trove of Genes Key to Kidney Cancer
JACKSONVILLE, Fla. — A genomic analysis of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, from 72 patients has uncovered 31 genes that are key to development, growth and spread of the cancer, say researchers from Mayo Clinic in Florida. Eight of these genes had not been previously linked to [...] (Source: Mayo Clinic Jacksonville News)
Source: Mayo Clinic Jacksonville News - July 1, 2014 Category: Hospital Management Source Type: news

In conversation with “e-Patient Dave”
“e-Patient Dave” is a leading advocate for engaging patients in their care and allowing patients to access their medical records. He also coauthored Let Patients Help: A Patient Engagement Handbook. He was diagnosed in 2007 with metastatic renal cell cancer.  In this conversation, Dave discusses his views on the relationship with the patient in patient care and patient safety.  (http://webmm.ahrq.gov/perspective.aspx?perspectiveID=159)  (bbj)   (Source: Midcontinental Region News)
Source: Midcontinental Region News - June 30, 2014 Category: Databases & Libraries Authors: liaison Tags: General Interest Health Sciences Libraries Public Libraries Source Type: news

Podcast: About Kidney Cancer
Your browser does not support native audio, but you can download this MP3 to listen on your device. Renal cell carcinoma (RCC) is the most common type of kidney cancer, with more than 200,000 new cases of RCC diagnosed worldwide each year, and 25-30% of kidney cancer patients diagnosed with metastatic disease. With advancements in medical science, patients with advanced RCC can now have better chances of surviving cancer as Professor Dr. Marniza Saad informs us  06/27/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 27, 2014 Category: Cancer & Oncology Source Type: news

Podcast: About Kidney Cancer
Your browser does not support native audio, but you can download this MP3 to listen on your device. Renal cell carcinoma (RCC) is the most common type of kidney cancer, with more than 200,000 new cases of RCC diagnosed worldwide each year, and 25-30% of kidney cancer patients diagnosed with metastatic disease. With advancements in medical science, patients with advanced RCC can now have better chances of surviving cancer as Professor Dr. Marniza Saad informs us  06/27/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 27, 2014 Category: Urology & Nephrology Source Type: news

Podcast: About Kidney Cancer
Your browser does not support native audio, but you candownload this MP3 to listen on your device.Renal cell carcinoma (RCC) is the most common type of kidney cancer, with more than 200,000 new cases of RCC diagnosed worldwide each year, and 25-30% of kidney cancer patients diagnosed with metastatic disease. With advancements in medical science, patients with advanced RCC can now have better chances of surviving cancer as Professor Dr. Marniza Saad informs us 06/27/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 27, 2014 Category: Urology & Nephrology Source Type: news

Gene in brain linked to kidney cancer, researchers say
A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer, researchers are reporting. The research reveals that the gene NPTX2, plays an essential role in this cancer type, which is resistant to common chemotherapy and has a five-year overall survival rate of less than 10 percent in patients with metastatic disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 24, 2014 Category: Science Source Type: news

Mayo Clinic researchers say gene in brain linked to kidney cancer
(Mayo Clinic) A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer, researchers from Mayo Clinic in Florida are reporting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 24, 2014 Category: Global & Universal Source Type: news

Mayo Clinic Researchers Say Gene in Brain Linked to Kidney Cancer
JACKSONVILLE, Fla. — A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer, researchers from Mayo Clinic in Florida are reporting. https://www.youtube.com/watch?v=jJ_8vv97wIA Their study, published in Cancer Research, reveals that the gene NPTX2, plays an essential role in this cancer [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - June 24, 2014 Category: Research Source Type: news

“Mayo Clinic Researchers Say Gene in Brain Linked to Kidney Cancer,” Mayo Clinic Cancer Center
A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer, researchers from Mayo Clinic in Florida are reporting. In this video, John A. Copland, PhD, molecular biologist and this study's senior investigator, discusses the findings of a recent study, which was published in Cancer Research. Mayo Clinic Cancer Center is one of the 25 NCCN Member Institutions. ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - June 24, 2014 Category: Cancer & Oncology Source Type: news

Radiation Therapy: Curative Option for RCC?Radiation Therapy: Curative Option for RCC?
Dr. Gert De Meerleer discusses the use of stereotactic body radiation therapy (SBRT) to control and potentially cure limited metastatic disease in renal cell carcinoma. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2014 Category: Consumer Health News Tags: Hematology-Oncology Expert Interview Source Type: news

An Unused Curative Option in RCC?An Unused Curative Option in RCC?
Dr. Gert De Meerleer discusses the use of stereotactic body radiation therapy (SBRT) to control and potentially cure limited metastatic disease in renal cell carcinoma. Medscape Oncology (Source: Medscape Nephrology Headlines)
Source: Medscape Nephrology Headlines - June 23, 2014 Category: Urology & Nephrology Tags: Hematology-Oncology Expert Interview Source Type: news

MET is a potential target across all papillary renal cell carcinomas
Recent report of MET inhibition strengthened the role of c–Met inhibition across pRCC.06/17/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 17, 2014 Category: Cancer & Oncology Source Type: news

Six Organizations Receive Grants from NCCN and Pfizer for Health Care Quality Improvement Programs in Rare Cancers
The NCCN Oncology Research Program (ORP) and Pfizer Independent Grants for Learning & Change have awarded six independent grants to implement quality improvement and health care professional education in renal cell carcinoma and hematologic malignancies. FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP), in collaboration with Pfizer Independent Grants for Learning & Change (IGLC), recently awarded six independent grants to hea... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - June 11, 2014 Category: Cancer & Oncology Source Type: news

ASCO 2014 Renal Cell Carcinoma Abstracts
Abstracts mentioning renal cell carcinoma (kidney cancer) from the 2014 ASCO Annual Meeting in Chicago.05/31/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 31, 2014 Category: Cancer & Oncology Source Type: news

Cell-Cycle Gene Test Shows Early Promise in Clear Cell RCC - See more at: http://www.onclive.com/conference-coverage/aua-2014/Cell-Cycle-Gene-Test-Shows-Early-Promise-in-Clear-Cell-RCC#sthash.DhoRovxs
A cell-cycle gene array test demonstrated independent value for predicting metastatic progression after surgery for organ-confined renal cell carcinoma (RCC) of clear cell histology...05/21/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 21, 2014 Category: Cancer & Oncology Source Type: news

Treatment Choices in mRCCTreatment Choices in mRCC
How to make the choice of treatment options for patients with metastatic renal cell carcinoma? Dr. Viktor Grünwald, author of a recent review, sorts out the evidence. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Expert Interview Source Type: news

Tailoring Therapy in Renal Cell CarcinomaTailoring Therapy in Renal Cell Carcinoma
How to make the choice of treatment options for patients with metastatic renal cell carcinoma? Dr. Viktor Grünwald, author of a recent review, sorts out the evidence. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Expert Interview Source Type: news

IL-2 for Kidney Cancer Offers CureIL-2 for Kidney Cancer Offers Cure
High-dose interleukin-2 is still a viable treatment option for metastatic renal cell carcinoma, because it is the only truly curative option for advanced disease. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 12, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Surgical strategies available for renal cell carcinoma
Prof Wood talks to ecancertv at the EIKCS conference about the different surgical strategies available for approaching renal cell carcinoma with inferior vena cava invasion and their outcomes post-surgery.05/07/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 7, 2014 Category: Cancer & Oncology Source Type: news

Study Confirms Clinical Benefit for Interleukin-2
Patients with metastatic renal cell carcinoma face a poor prognosis; currently, 30% of patients already have metastatic disease at the time of diagnosis, according to national data.05/07/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 7, 2014 Category: Cancer & Oncology Source Type: news